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Introduction
Tryptophan was initially discovered by Hopkins and Cole in 
1901 after isolation from casein protein.1 Tryptophan is 1 of the 
8 essential amino acids that cannot be synthesized by the human 
body.2 Although tryptophan has the lowest concentration in the 
body of all the essential amino acids, only very low concentra-
tions are required for healthy nutrition.2 Tryptophan has been 
extensively studied due to its important metabolic functions, 
which include the synthesis of hormones such as kynurenine, 
serotonin, tryptamine, melatonin, and essential coenzymes, par-
ticularly nicotinamide adenine dinucleotide (NAD+), that are 
known to play critical physiological functions.2,3
Tryptophan has been associated with several clinical disor-
ders. Historically, tryptophan was associated with pellagra, a 
dermatological condition associated with deficiency in trypto-
phan and niacin.4,5 Most notably, tryptophan is involved in 
behavioral changes through synthesis of serotonin and 
tryptamine, 2 major players in neuropsychiatric disorders.2,6 
Tryptophan deprivation induces depression, separation 
anxiety,7,8 chronic fatigue syndrome, and fibromyalgia. 
Furthermore, increasing evidence shows the role of tryptophan 
in brain tumor pathogenesis9,10 and other cancer types, such as 
colorectal, breast, and bladder cancers.7,11–13
Interestingly, tryptophan deprivation also sensitizes acti-
vated T-cells to apoptosis in novo14 and favors the induction of 
regulatory T-cells (Tregs) via dendritic cells.15,16 Although the 
role of tryptophan in regulating the immune system has been 
previously described,17 research in this area has been scarce 
until recently. Several recent publications highlighted the 
involvement of tryptophan in inflammation, immune activa-
tion, and immune tolerance,11,13,18–20 raising awareness of tryp-
tophan catabolism and its role in the immune system.
Kynurenine is an important biosynthetic pathway in trypto-
phan catabolism.21 Moreover, most of the immunologic function 
accredited to tryptophan was attributed to the kynurenine 
pathway.3,18,22,23 More importantly, the kynurenine pathway is 
essential for the de novo synthesis of NAD+24 and acts as a sub-
strate for several other molecules.25,26 Of note, the NAD+ levels 
have been described as very volatile; therefore, the de novo syn-
thesis of NAD+ plays an important role in maintaining adequate 
NAD+ levels.27 Quinolinic acid (QUIN), a product of tryptophan 
degradation, was found to be essential for de novo synthesis of 
NAD+ and may serve as a precursor of NAD+ in the tryptophan/
kynurenine pathway. Although QUIN is neurotoxic,9,22,28 recent 
publications have underscored the capacity of NAD+ to regulate 
T-cell fate and promote homeostasis29–31 independent of the 
classical pathways that have considered cytokine environment 
and transcription factors as the major regulator of CD4+ T-cell 
differentiation and adaptive immune response.
The kynurenine pathway is initiated by 2 rate-limiting 
enzymes: indoleamine 2,3-dioxygenase (IDO) and tryptophan 
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2,3-dioxygenase (TDO), which are essential in tryptophan 
catabolism. Indoleamine 2,3-dioxygenase has been found 
in many immune cells, such as dendritic cells (DCs) and 
macrophages,32,33 whereas TDO has been found in the liver 
and neurons.32 Moreover, both IDO34 and TDO11 are present 
in several malignancies such as prostate, colorectal, pancreatic, 
and breast cancers. Increasing evidence points toward an 
important role of IDO in the regulation of the immune 
system.12,17,35 Interestingly, IDO is involved in the activation 
of the protein aryl hydrocarbon receptor (AhR),32 a ligand-
activated transcription factor that regulates the immune system 
and inflammatory responses.36–38 Indeed, on activation, AhR 
can promote the differentiation of type 1 regulatory cells 
(Tr1)39,40 and control Treg/TH17 differentiation,37,41 critical 
CD4+ T-cell subsets involved in immunosuppression or pro-
inflammatory responses. Furthermore, IDO promotes long-
term tolerance by DCs through transforming growth factor β 
(TGF-β) in a noninflammatory context in novo.42,43
Collectively, these findings indicate the existence of other 
pathways that regulate the immune system. These alternative 
pathways play key roles in a myriad of diseases and may serve as 
an alternative to develop novel therapeutic approaches. In this 
mini-review, we discuss the current knowledge of the increasing 
evidence of tryptophan and its role in immune regulation, with 
an overview of the kynurenine/QUIN/NAD+ pathway and 
emphasize missing links for which more research is needed. We 
also discuss possible models and key players in immune regula-
tion via the kynurenine/QUIN/NAD+ pathway.
Tryptophan and Its Role in Immune Responses
Tryptophan has been implicated in many metabolic processes, 
including the metabolic synthesis of major proteins, such as 
kynurenine, serotonin, tryptamine, melatonin, and other 
coenzymes, particularly NAD/NADP (NAD phosphate).2 
Although these metabolic processes are critical, the role of 
tryptophan in the immune system is still poorly understood.
The kynurenine pathway is a major route for the catabolism 
of tryptophan and has an important role in the immune 
system.17,21,32,44 The kynurenine pathway is initiated by cleav-
age of the indole ring, which is initiated by tryptophan 
2,3-dioxygenase 2 (TDO-2), indoleamine 2,3-dioxygenase 1 
(IDO-1), or IDO-2, which shares similarities with IDO-1 but 
has limited catabolic activity compared with TDO-2 and 
IDO-1.22,45–47 TDO-2 has been found primarily in the liver 
and central nervous system (CNS), but recent publications 
have identified TDO-2 in different types of cancer.10,23 TDO-2 
suppresses antitumor immune responses and promotes tumor 
cell survival.48 Furthermore, TDO-2 promotes metastasis in 
breast cancer49,50 and the progression of lung cancer in vivo.51 
Moreover, enzymatically active TDO-2 is overexpressed in a 
significant proportion of human tumors.10 TDO-2 overexpres-
sion has been correlated with poor prognosis in high-grade 
gliomas.45 Current immunosuppressive therapies aim to inhibit 
TDO-2.11 Pilotte et al10 were able to restore the ability to 
reject TDO-expressing tumors using a self-developed TDO-
inhibitor (compound 680C91). Furthermore, Crosignani et al52 
presented their preclinical assessment of a TDO-2-inhibitor 
(iTeos) in the 29th Annual Meeting of the Society for 
Immunotherapy Cancer, with similar results on a p815 masto-
cytoma tumor model overexpressing TDO-2.
Contrary to TDO-2, IDO-1 is found extrahepatically and 
is present in several immune cells.35,53,54 Indeed, IDO-1 is 
present in human tumor cells and can prevent tumor cell 
rejection due to a lack of accumulation of specific T-cells.34 
Moreover, IDO-1 is upregulated by several pro-inflammatory 
molecules.55,56 The interaction between IDO-1 and DCs has 
been the most studied to date. The rapid switch in function 
from immunogenic to tolerogenic activity is dependent on 
IFN-γ, whereas the tolerogenic phenotype is conferred by 
IDO-1. Indeed, IFN-γ is a potent activator of gene expres-
sion and enzymatic activity of IDO-1.57,58 The tolerogenic 
phenotype induced by IDO-1 plays a double role in immune 
responses. Indoleamine 2,3-dioxygenase expands human 
CD4+CD25highFoxp3+ Tregs by promoting maturation of 
DCs.59 Second, IDO-expressing DCs suppressed allograft 
rejection by expansion of CD4+CD25highFoxp3+ Tregs.33 In 
contrast, IDO promotes tolerance toward tumor cells and can 
promote resistance toward immunotherapies.60 More impor-
tantly, tumors expressing Foxp3+/IDO+ are associated with 
more advanced disease.44 Interestingly, therapies targeting 
IDO have been shown to be effective against different types 
of cancer by measuring messenger RNA.12,61,62 Similar inter-
actions between IDO and other cells of the immune system 
have been described. Among these immune cells, we found 
interactions with macrophages,54,63 mast cells,32,42 and 
Tregs.64,65
The initial activation models for the kynurenine pathway 
showed a redundant activation through TDO-2 and IDO-1.22 
However, present evidence suggests specific roles for each of 
these enzymes in the tryptophan catabolic pathway. As Puccetti 
notes, in the early events of systemic inflammation, cortisol 
induces the release of acute phase proteins such as TDO-2. 
TDO-2 release activates the AhR, as explained below, tran-
scribing interleukin (IL)-10 and IDO-1. Finally, the transcrip-
tion of IL-10 and IDO-1 will create homeostasis.47 This model 
indicates different gene activation processes and roles for 
TDO-2 and IDO-1.47,66
Immune Implications of the AhR and Tryptophan 
Catabolic Enzymes
We have recently shown that kynurenine was able to promote 
mast cell activation by activating the AhR.32 As previously 
reported, activation of AhR has been linked to activation of 
Tr1 and to control of Tregs and TH17 differentiation.39–41 
Interestingly, most immune cells—T-cells, B cells, mac-
rophages, DCs, and natural killer cells—express AhR.67 
These findings suggest an important role of AhR in regulation 
of the immune system.
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AhR is a transcription factor in the cytosol that is activated 
on ligand binding.67,68 AhR is a key regulator of xenobiotic 
toxicity, such as 2,3,7,8,9-tetracholodibenzo-p-dioxin (TCDD) 
and dioxin, the most prominent member of the environmental 
pollutants.36,67 However, AhR has also been identified as a key 
player in several signaling cascades and other cell biological 
events. Most likely, one of the most interesting and newly iden-
tified aspects of AhR is its involvement in immune regulation 
and tolerance.
AhR has been shown to regulate CD4+CD25+Foxp3+ Tregs 
as well as TH17 cell fate, which are 2 major subsets of the adap-
tive immune system; extensive studies have underscored the 
importance of Tregs and TH17 cell balance.69–71 Indeed, Tregs 
are responsible for homeostasis and immune tolerance and are 
very robust immunosuppressive cells, whereas TH17 cells are 
considered to be pro-inflammatory cells involved in a myriad of 
diseases including autoimmunity.72,73 Interestingly, AhR has 
been found to control Tregs and TH17 cell differentiation in 
experimental autoimmune encephalomyelitis (EAE),41 which 
are the most commonly used experimental model for multiple 
sclerosis. In this study, the authors found that AhR activation by 
TCDD controls Treg development in vivo, suppressing the 
severity of EAE. Furthermore, activation of AhR via another 
ligand, 6-formylindolo 3,2-b carbazole (FICZ), increased TH17 
differentiation, thereby increasing the severity of EAE.41 
Interestingly, FICZ has been shown to control Tregs via the 
activation of epidermal DCs when keratinocytes were exposed 
to UV-B light.74 Indeed, UV-B light activation of AhR is 
believed to generate FICZ in the skin.75 FICZ and TCDD 
have shown exert different effects on TH17/Treg development 
either in vitro or in vivo.76 It is now clear that AhR modulates 
the immune system in response to ligands of diverse origin.37 
Furthermore, AhR ligands affect several pathways and responses 
depending on the tissue/cellular context.36 There is a range of 
potential physiological ligands for AhR.77 However, the exact 
molecular mechanisms remain elusive and are subject of current 
research.
The role of AhR as a mediator of homeostasis and immune 
tolerance is further supported by its involvement in the regulation 
of type 1 Tregs (Tr1). Tr1 cells have the capacity to coproduce 
IFN-γ and IL-1030,78 and have emerged as an important immu-
nosuppressive CD4+ T-cell subset that dampens inflammatory 
responses, promotes transplant tolerance, and prevents tissue 
damage.29,79,80 Gandhi et al40 observed induction of Tr1 cells by 
activation of AhR through TCDD in human cells. Interestingly, 
in the same study, they found that adding TGF-β1 to the activa-
tion of AhR through TCDD induced functional Tregs.40 
Independent of the type of regulatory cell that is activated, AhR 
activation through TCDD induces a significantly higher expres-
sion of IL-10 in human cells.40 Simultaneously, Apetoh and 
Quintana39 corroborated the findings from Gandhi. Furthermore, 
they showed that AhR interacts with c-Maf, a transcription fac-
tor shown to regulate synthesis of IL-10,81 to contribute to 
Tr1-cell differentiation.39 The high expression of IL-10 could 
protect animals from EAE. Tullius et al29 and Wang et al31 have 
also shown that IL-10 is capable of promoting homeostasis and 
protecting from EAE via the direct activation of Tr1 cells.
As previously mentioned, the metabolites generated from 
the tryptophan/IDO/TDO pathway act as ligands for AhR.67 
Indeed, the IDO-1/AhR interaction appears to be a more 
effective pathway for 2 main reasons: it is self-regulated because 
AhR presides over the regulatory proteolysis of IDO-1, and 
it acts in a feed-forward loop initiated by kynurenine, fol-
lowed by AhR activation, promoting IDO-1 transcription.47 
Interestingly, the IDO-1/AhR axis is very dependent on the 
presence or absence IL-6, an essential pro-inflammatory 
cytokine for the induction of TH17 cells, and it can be antago-
nized by IL-10.82
The absence of IL-6 is paramount for the IDO-1/AhR axis 
to be effective in IL-10 production and to create homeostasis.36 
However, in the early phases of inflammation, IL-6 is required as 
an initial defense mechanism.83,84 During the early phase of 
inflammation, the source of kynurenine must be from some-
where other than the IDO-1/AhR axis.47 Once the IDO-1/
AhR axis is started through an external kynurenine source, AhR 
can repress IL-6 via the transcription of IL-10.36 An interesting 
model suggested by Puccetti indicates cortisol as an outsource 
for kynurenine through TDO-2.47 Cortisol is released with pro-
inflammatory cytokines in the early phases of inflammation and 
releases acute phase proteins by the liver, one of which is TDO-
2.47,48,85 Interestingly, clinical trials indicated that cortisol and 
IL-6 increased the percentages of Tregs.84 Furthermore, both 
cortisol and IL-6 can produce high amounts of TDO-2 by the 
liver activating the kynurenine pathway.86 Indeed, other sources 
for the activation of AhR might be involved in this process and 
warrant further investigation.
Immunoregulatory Properties of NAD+ and 
Tryptophan
The major catabolic pathway of tryptophan is the kynurenine 
pathway, which ultimately leads to biosynthesis of NAD+,18 a 
vital cofactor that can rewire metabolism, activate sirtuins, and 
maintain mitochondrial fitness.87
Nicotinamide adenine dinucleotide was originally discov-
ered by Sir Arthur Harden and his colleagues in 1906.88 
However, its key role in hydrogen transfer in biochemical reac-
tions was not discovered until 1935.87 Nicotinamide adenine 
dinucleotide plays an important role in energy metabolism, but 
the roles of NAD+ have expanded beyond its initial function as 
a coenzyme linking cellular metabolism to several signaling 
and transcriptional events.27,29,30,87,89,90
One of the most interesting newly discovered roles of NAD+ 
is probably its involvement in homeostasis and immune responses. 
Data increasingly support the notion of NAD+-regulating 
immune responses. For example, NAD+ regulates cytokine pro-
duction of peripheral blood lymphocytes and monocytes.91,92 
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Based on these findings, we investigated the role of NAD+ and 
T-cells. We found that intraperitoneal injections of NAD+ pro-
tected mice against autoimmune diseases and prolonged allograft 
survival after skin transplantation.29,30 In our studies, NAD+ 
induced a systemic increase in IL-10 despite the reduction in 
Tregs and increase in TH17 cells. The increased IL-10 production 
was mediated via the immunosuppressive Tr1 cells. Moreover, 
NAD+ induced T-cell differentiation, despite the cytokine milieu 
and well-established transcription factors. Interestingly, a 
genome-wide gene expression profile assessed by microarray 
analysis showed tryptophan hydroxylase 1 (Tph1) to be upregu-
lated under the influence of NAD+, mostly described on mast 
cells. Collectively, our data indicate NAD+ as a potent immune 
regulator through tryptophan catabolism.
Several publications have indicated a strong relation 
between NAD+ and tryptophan, particularly with the kynure-
nine pathway.27,89,93,94 Furthermore, NAD+ is essential for cells 
under physiological stress to avoid cell damage.17 Nicotinamide 
adenine dinucleotide can be synthesized through niacin, which 
is typically present in an adequate diet2,87,94 and is the main 
source of NAD+ synthesis or de novo through tryptophan and 
the kynurenine pathway.27,95
De novo synthesis of NAD+ starts with the catalysis of trypto-
phan by either TDO-2 or IDO-195 into formylkynurenine fol-
lowed by conversion into l-kynurenine. Three more enzymatic 
reactions described elsewhere9 lead to the conversion into 
2-amino-3-carboxymuconate semialdehyde (ACMS). ACMS 
can go either through an enzymatic pathway leading to total oxi-
dation or through a nonenzymatic cyclization to QUIN. QUIN 
is essential for de novo synthesis of NAD+.17,87 Interestingly, 
QUIN has been shown to be neurotoxic.28,96 Moreover, QUIN 
accumulates in human glioma cells and is associated with malig-
nant phenotypes.97 Furthermore, QUIN was found to confer 
resistance of gliomas to oxidative stress. The cytotoxic properties 
of QUIN in the brain have extensively been discussed in the lit-
erature, but very little is known about its role in immune responses. 
Nicotinamide adenine dinucleotide has been found to induce 
programmed cell death and hinder Tregs.98,99 Although we were 
able to confirm that NAD+ induces apoptosis of naïve CD4+ 
T-cells and reduces the number of Tregs,29 CD4+ T-cells that 
were differentiated into TH1, TH2, TH17, and iTreg were pro-
tected against apoptosis by NAD+.
Our previous studies showed the importance of the trypto-
phan/NAD+ pathway in inflammation, including autoimmune 
diseases and transplantation. These studies were performed in 
the context of antigen and antigen presentation. Our unpub-
lished data indicate that the NAD+/tryptophan signaling path-
way can trigger innate and adaptive immune responses in the 
absence of antigen. This is consistent with previous studies 
reporting that tryptophan administration promotes wound 
healing.100 However, the effects of exogenous tryptophan in 
immune responses have not been well studied. Interestingly, a 
previous study by Swanson et al101 showed that exogenous 
addition of tryptophan to recover lung interstitial antigen-pre-
senting cells (APCs)–induced T-cell proliferation in mixed 
leukocyte reactions. Of note, the addition of exogenous trypto-
phan can restore pathogens and replication of some bacteria 
and viruses43; thus, further studies are required to elucidate the 
role of exogenous tryptophan in immune responses.
Antigen-presenting cells play a unique role in the regulation 
of adaptive immune responses due to their ability to capture, 
process, and present antigens via their major histocompatibility 
complex (MHC) cell surface molecule to the T-cell receptor 
(TCR) to mount a restricted MHC immune response.102–104 
DCs are still considered the major APCs bridging innate and 
adaptive immune responses.105,106 The mode of action of DCs 
is mediated through at least 3 signals: (1) TCR activation, (2) 
activation of co-stimulatory molecules, and (3) secretion of 
chemokines and pro-inflammatory cytokines.105 In addition, 
DCs can regulate innate and adaptive immune responses by 
recognizing pathogen-associated molecular patterns, such as 
microbial nucleic acids, lipoproteins, and carbohydrates, or dam-
age-associated molecular patterns that are released from injured 
cells via intracellular or surface-expressed pattern recognition 
receptors (PRRs).107 Thus, our unpublished data, indicating that 
the tryptophan/NAD+ pathway can trigger the immune system 
in the absence of pathogen invasion or PRRs’ activation, suggest 
a novel cellular and molecular signaling pathway distinct from 
the classical ag-APCs (DCs)-MHCII-TCR signaling machin-
ery. It would therefore be interesting to further investigate 
the path used by tryptophan/NAD+, particularly the cells and 
molecules involved.
Tryptophan and NAD+ in the CNS
Active interactions between the CNS and the immune system 
are essential to maintain CNS integrity and homeostasis. The 
intact blood-brain barrier allows traffic of peripheral immune 
cells, CNS neurons and glia regulate macrophage and lympho-
cyte responses, and microglia play key roles in both innate and 
adaptive immune responses, providing the CNS with the stra-
tegic means to respond to pathogens. Thus, the past 30 years 
have seen significant changes in notions of CNS immune priv-
ilege. The immune implications of tryptophan have begun 
to extend into the CNS as well. Tryptophan is also the sole 
precursor of an important neurotransmitter, serotonin, or 
5-hydroxytryptophan. Serotonin is synthesized from trypto-
phan through hydroxylation and decarboxylation, processes 
that are catalyzed by tryptophan hydroxylase (Tph) and the 
aromatic acid decarboxylase, with Tph being the rate-limiting 
step in the synthesis. Of the 2 isoforms of Tph, Tph1 is 
expressed both in the periphery (skin, enterochromaffin cells 
of the gut, mast cells, and the pineal gland) and in the CNS, 
and Tph2 is expressed in neurons of the central, peripheral, 
and enteric nervous systems. Indeed, tph1-null mice have 
gross abnormalities such as an overall size reduction, altered 
morphology of the rhombencephalon regions and neopallial 
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cortex, alterations in gait dynamics, and reduced motivation 
locomotion.108 Tph2-null mice show alterations in develop-
mental milestones, brain-to-body weight ratio, and substantial 
deficits in numerous validated tests of social interaction and 
communication with highly repetitive and compulsive behav-
iors.109 There appears to be no substantial overlap in the expres-
sion of the 2 tph isoforms by adulthood. Dietary tryptophan 
can also regulate serotonin synthesis in the brain and can affect 
mood, behavior, and cognition. Serotonin synthesis is thus an 
important tryptophan pathway and is a topic of intense research 
due to its broad impact as a neuromodulator. Multiple lines of 
evidence support its association with numerous neuropsychiat-
ric conditions such as Parkinson disease, schizophrenia, depres-
sion, anxiety, and, of great significance, autism.
Autism, which is characterized as both a neurodevelopmen-
tal and a neuropsychiatric disease, has also distinctly evolved 
into a disease of the immune system.110–112 One or more core 
behavioral symptoms, such as impaired social recognition, 
reduced social interactions, communication deficits, increased 
anxiety, motor stereotypies, repetitive behaviors, insistence on 
sameness, and restricted interests, identify autism. The Centers 
for Disease Control and Prevention estimates that ~1 in 88 
children is diagnosed with autism each year, more than those 
diagnosed annually with cancer, diabetes, and AIDS combined. 
Currently, approximately $35 billion in direct and indirect care 
costs are spent annually for autism.113 The annual cost of caring 
for patients with autism is believed to reach $500 billion by 
2025, with outside estimates reaching $1 trillion.114 Therefore, 
it is critical to gain mechanistic insights into multiple pathways 
coexisting in autism that will lay the foundation for new thera-
peutic opportunities.
Close associations between the serotonin and kynurenic path-
ways occur in tryptophan metabolism that are strongly influenced 
by the activity of the immune system. Quinolinic acid, a down-
stream product of the kynurenic pathway, is the structural precur-
sor of NAD+, a critical energy carrier in mitochondria. Therefore, 
decreased tryptophan metabolism via either serotonin or QUIN 
will alter brain development, neuroimmune activity, and mito-
chondrial function. Interestingly, decreased tryptophan metabo-
lism affecting both serotonin and kynurenic pathways has been 
linked to autism. Even a short-term reduction in the levels of 
tryptophan exacerbates repetitive, compulsive behaviors (eg, flap-
ping, rocking, and whirling) in drug-free adults with autism.115 
Serotonin in the blood is stored in platelets that undergo endocy-
tosis via the serotonin transporter. Abnormal blood levels of sero-
tonin produce autistic-like behaviors, such as impaired social 
communication and avoidance of new situations.116 Children 
with autism show a diminished capacity of whole-brain or 
regional brain serotonin synthesis that affects language produc-
tion and sensory integration.117,118 There are reports of reductions 
in not only serotonin concentrations but also the kynurenic acid 
levels in the cerebrospinal fluid of autistic children.119,120 
Diminished levels of NAD+ and plasma tryptophan in parallel 
with increased levels of oxidative stress have been reported in 
children with autism.121,122 In addition, urinary levels of trypto-
phan are reduced in patients with autism.123
Taken together, these results illustrate the critical need for a 
better understanding of the detailed mechanistic actions of 
tryptophan and NAD+ from cellular, molecular, and immuno-
logic perspectives at distinct developmental time points in the 
CNS, which will aid in designing novel treatment strategies 
and bring new hope for neuroimmunological diseases such as 
autism. In addition, changes in tryptophan metabolism and 
pathway intermediates may serve in the development of new 
diagnostic assays for CNS immunologic disorders.
Conclusions
Increasing evidence indicates the important role of trypto-
phan catabolism in immune responses via the kynurenine 
pathway in vivo.51,124,125 However, the exact mechanisms 
remain unknown. Based on the findings shown here, NAD+ 
might be responsible for the newly found functions of trypto-
phan in immune responses. In particular, de novo synthesis of 
NAD+ through QUIN, one of the catabolites of the kynure-
nine pathway, appears to have an important role in immune 
regulation and tolerance (Figure 1). However, tryptophan cat-
abolites appear to have contradictory functions, depending on 
where they are involved and warrant further investigation. 
Furthermore, mast cells, although they are not typical APCs, 
might play an important role in the tryptophan/QUIN/
NAD+ pathway regulating T-cell activation. Clearly, the field 
of immunology shaped by tryptophan and NAD+ is poised 
for several exciting discoveries in the future.
Figure 1. Newfound functions of tryptophan in immune responses might 
be influenced by NAD+. De novo synthesis of NAD+ through QUIN 
appears to have an important role in immune regulation and tolerance. 
CNS indicates central nervous system; IDO, indoleamine 
2,3-dyoxygenase; KYNp, kynurenine pathway; NAD+, nicotinamide 
adenine dinucleotide; QUIN, quinolinic acid; TDO, tryptophan 
2,3-dyoxygenase; Tph1, tryptophan hydroxylase 1; Tph2, tryptophan 
hydroxylase 2; Tregs, regulatory T-cells; TRP, tryptophan.
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